---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-052295"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:18:23.283842+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics updates pipeline timelines, reports cash runway and share count in corporate deck

## Summary
- Cash on hand sufficient to fund all clinical and preclinical programs in development.
- 13.2 million shares outstanding as of June 6, 2025; no outstanding debt noted.
- HT-001 Phase 2a open-label PK data expected Q1 2025; full dataset Q4 2025.
- HT-KIT IND submission targeted Q1 2026; GLP tox & GMP API manufacturing initiated Q1 2025.
- HT-ALZ pre-IND meeting submission planned for 2025; 505(b)(2) pathway pursued.

## SEC filing metadata
- accession: 0001213900-25-052295
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390025052295/0001213900-25-052295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390025052295/ea0245073-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-052295
- JSON: https://secwatch.observer/filing/0001213900-25-052295.json
- Plain text: https://secwatch.observer/filing/0001213900-25-052295.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.